Printer Friendly

NEORX COMMENCES STUDY TO QUALIFY NEW ONCOTRAC MANUFACTURER

 SEATTLE, May 11 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced it has commenced a limited clinical trial requested by the FDA to qualify Boehringer Ingelheim (BI) as the manufacturer of its OncoTrac(R) Small Cell Lung Cancer Imaging kit, an imaging agent to stage patients with small cell lung cancer.
 The trial, the results of which are expected to be filed with the FDA during the third quarter of this year, is being conducted at several medical centers in the United States.
 "We believe qualifying BI's wholly-owned subsidiary, Dr. Karl Thomae GmbH as the manufacturer of OncoTrac is the last step necessary to gain marketing approval in the U.S.," said Paul Abrams, M.D., J.D., NeoRx's president and CEO. "In January 1992, we announced receipt of a letter from the FDA indicating that it had no questions on the clinical utility of the product."
 OncoTrac Small Cell Lung Cancer Imaging is the only lung cancer imaging product that has been through Phase III trials and the only antibody-based cancer imaging product that has been compared to the entire standard battery of diagnostic tests (CT-head, chest X-ray or CT-chest, CT-abdomen, bone scan).
 "We believe that our data supports using OncoTrac products as the first test to stage patients with small cell lung cancer because it has the highest sensitivity (84 percent) of any test, and a positive predictive value of 97 percent," said Dr. Abrams. "Such a high positive predictive value means that a positive finding from this one test is highly likely to be accurate. This data indicates that, by decreasing the number of tests, OncoTrac imaging may decrease the time and expense of determining how far the lung cancer has spread. This in turn determines what treatment the patient should receive and save other costs by preventing patients from receiving unnecessary and potentially toxic therapy. These characteristics will position this product very well for the cost-containment, diagnostic efficiency pressures that will occur under health care reform proposals."
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA its OncoTrac Small Cell Lung Cancer Imaging Product and has completed a phase III trial for a non-small cell lung cancer imaging agent. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in pre-clinical testing.
 -0- 5/11/93
 /CONTACT: Robert M. Littauer, vice president and chief financial officer of NeoRx, 206-286-2519; or Bonnie K. Sterling of Noonan/Russo Communications, 212-979-9180, for NeoRx./
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU:

SM-LR -- NY016 -- 6866 05/11/93 08:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1993
Words:447
Previous Article:SYNCOR SIGNS LETTER OF INTENT TO SELL HOME INFUSION BUSINESS; W.R. GRACE & CO. TO PURCHASE EIGHT HOME CARE SITES
Next Article:AFFYMETRIX APPOINTS TOP MANAGEMENT
Topics:


Related Articles
NEORX SIGNS COLLABORATION AND RESEARCH AGREEMENT WITH ORGANON INTERNATIONAL ON COLON CANCER THERAPY
NEORX CORPORATION AND STERLING WINTHROP INC. SIGN LICENSE AGREEMENT FOR CANCER RADIOIMMUNOTHERAPY TECHNOLOGY
NEORX AND BOEHRINGER INGELHEIM COMPLETE STRATEGIC ALLIANCE
NEORX DEMONSTRATES EFFICACY IN ANIMALS OF TWO THERAPEUTIC PRODUCT LINES
NEORX DIVIDEND NOTICE
NEORX'S AVICIDIN ADVANCES IN PHASE I II CANCER THERAPY TRIALS
NEORX ANNOUNCES $7.0 MILLION PRIVATE PLACEMENT OF SECURITIES TO INSTITUTIONAL INVESTORS
NEORX DIVIDEND NOTICE
BIOSYS ANNOUNCES AGREEMENT WITH NEORX TO PRODUCE THERAPEUTIC PROTEINS
NEORX ANNOUNCES AGREEMENT WITH BIOSYS TO PRODUCE THERAPEUTIC PROTEINS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters